Table 4.

Diagnostic ncRNAs in thyroid cancer.

ncRNA	ncRNA Type	Source	Finding	Thyroid Samples	Ref.
miR-138-1-3p miR-139-5p miR-146b-5p miR-155miR-204-5p miR-222-3pmiR-29b-1-5p miR-31-5p miR-375 miR-551b-3p	miRNA	FNA	miRNA testing, recently commercialized as ThyraMIR, identified 64% of malignant cases and 98% of benign cases correctly.	Not known	[170]
miR-146b			Higher expression in PTC FNA samples	PTC	[171]
miR-132-3p miR-146a-5pmiR-17-5p miR-183-3p miR-222-3p miR-451a		Serum	miR-222-3p and miR-17-5p can accurately discriminate MTC from the benign nodule and healthy control groups	PTC, MTC, benign nodules and controls	[172]
miR-146a-5p miR-221-3p miR-222-3p			High pre-surgical expressionLow post-surgical expression	PTC	[173]
miR-146b miR-21 miR-221 miR-222			Higher expression in PTM serum samples		[174]
miR-146a-5p miR-199b-3p			Lower expression in PTC serum as compared to benign serum samples		[175]
let-7b-5pmiR-10a-5p			Higher expression in PTC serum as compared to benign serum samples
miR-423-5p			Higher expression in PTC serum samples		[176]
let-7a		Tissue	Lower expression in thyroid tumor samples	Not known	[58]
H19	lncRNA		Higher expression in thyroid tumor samples
H19			Lower expression in thyroid tumor samples as compared to benign samples	PTC	[127]
MALAT1			Higher expression in thyroid tumor samples		[123]
n340790				Not known	[119]
UNC5B-AS1				PTC	[124]

PTC: Papillary Thyroid Cancer; MTC: Medullar Thyroid Cancer; UNC5B-AS1: Unc-5 Netrin Receptor B-Antisense RNA 1; MALAT1: Metastasis Associated Lung Adenocarcinoma Transcript 1; FNA: Fine Needle Aspiration.